Kailera Therapeutics
CompanyUnited States
Kailera Therapeutics develops one asset, in phase 3 (ribupatide in obesity). Mostly peptide acting on Insulin/IGF-1 signalling, lipid and ceramide metabolism and GLP1R; based in the United States.
- 1
- Asset
- Furthest stage
- Phase 3
- 4
- Trials
- 2
- Signals
Pipeline
1Dual GLP-1 and GIP receptor agonist for metabolic disorders and weight loss
Phase 3, Peptide, Insulin/IGF-1 signalling, Lipid and ceramide metabolism, obesity, obesity with diabetes
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms7
- Trials4
- Signals10
- Similar companies6
Papers
ADA Scientific Sessions 2026 abstract, 6 Jun 2026
Waist-to-Height Ratio Outperforms BMI in Identifying Hepatic Steatosis and Fibrosis in U.S. Adults
ADA Scientific Sessions 2026 abstract, 6 Jun 2026